MarketCap
Facebook
X
Telegram
Timber Pharmaceuticals ROA Ratio | TMBR
Annual ROA Ratio Timber Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -188.59 | -59.43 | -130.01 | -3378.77 | -205.69 | -259.2 | -321.54 | -52.65 | -261.1 | -428.03 | -57.89 | - | -79.21 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -52.65 | -3378.77 | -451.84 |
Quarterly ROA Ratio Timber Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -307.61 | -206.24 | -141.54 | -207.55 | -221.2 | -144.55 | -123.76 | -102.34 | -139.32 | -118.04 | -98.86 | -166.44 | -239.09 | -209.59 | -192.29 | -343.94 | -347.85 | -371.02 | -297.53 | -536.03 | -748.63 | -769.96 | -695.56 | -814.35 | -617.16 | -451.48 | -358.68 | -477.47 | -399.99 | -557.25 | -358.68 | -465.51 | -456.93 | -670.14 | -471.57 | -593.13 | -556.38 | -475.55 | -221.02 | -222.85 | -269.5 | -231.44 | -4805.82 | -4863.55 | -4732.44 | -4707.14 | -111.5 | -37.1 | -6.71 | -8.13 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -6.71 | -4863.55 | -693.41 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-74.47 | $ 4.2 | -0.36 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
1.36 | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-55.34 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
-130.77 | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
1.78 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-176.62 | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
7.83 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-28.79 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-55.1 | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
8.51 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
-3565.14 | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
-21.64 | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-3.05 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
13.46 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-284.3 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-4.95 | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
-73.22 | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-56.43 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-36.84 | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-72.91 | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
-29.24 | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
18.35 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.31 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
-338.46 | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
-69.01 | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
26.31 | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-6.89 | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
-699.19 | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
-22.87 | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-106.53 | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
-314.78 | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
-58.51 | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
19.74 | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-12.01 | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
-23.1 | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
-26.84 | - | 8.07 % | $ 54 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Verona Pharma plc
VRNA
|
-36.57 | - | - | $ 69.7 B | Britain |